Erythropoietin regulates tumour growth of human malignancies
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
In addition to the chief function of erythropoietin (Epo) in promoting erythropoiesis, some other roles have been found in the brain and uterus. We have reported that signalling pathways of Epo and Epo receptor (EpoR) are involved in the tumourigenesis of ovarian and uterine cancers. To determine whether Epo plays a similar role in other malignancies, we studied the expression of Epo in several malignant human cell lines. We found that 24 malignant human cell lines examined express Epo and EpoR regardless of their origins, types, genetic characteristics and biological properties and secrete a very small amount of Epo individually and that most of them respond to hypoxic stimuli by enhanced secretion of Epo. To determine whether the Epo-EpoR pathway operates in tumours of these cell lines, we transplanted several cell lines into nude mice and confirmed the presence of Epo-responsive sites in xenografts in which the phosphorylation of the STAT5 (signal transducer and activator of transcription) is detectable. Furthermore, in nude mice we blocked the Epo signalling in xenografts of two representative cell lines, stomach choriocarcinoma and melanoma, by i.p. injections of EpoR antagonist and found inhibition of angiogenesis and survival of tumour cells leading to destruction of tumour masses and disturbances of phosphorylation of STAT5. In contrast, Epo mimetic peptide promotes angiogenesis and tumour cell survival. These findings suggest that Epo is indispensable for the growth and viability of malignant tumour and also that the deprivation of Epo signalling may be a promising therapy for human malignancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, ESA and RBC transfusions may have adverse immune-modulatory effects [126–129].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [128]
Citations
Cites
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617 · cited 3×
“Since Epo is a secreted protein (3,4) with hypoxia stimulating its secretion (22,23), and since tumours are hypoxic (29), we measured with an enzyme-linked assay (30) Epo protein in each culture medium under normoxia and anoxia.”
BackgroundMethodRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
(1999) · PubMed · Cited by 2,204
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579 · cited 1×
“Furthermore, studies of xenografts of ES cells with a loss of HIF-1α reveal attenuation of tumour growth and inhibition of angiogenesis (43,44); however, xenografts of ES cells with HIF-1α show tumour growth with abundant vascularity (43).”
BackgroundIhle, J. N. (1995) · Nature · doi:10.1038/377591a0 · Cited by 1,203 · cited 1×
“Binding Epo to its specific receptor (EpoR), which belongs to a family of cytokine receptors that have no tyrosine kinase domain, induces homodimerization of EpoR and the subsequent activation of a Janus kinase 2 (JAK2) through tyrosine phosphorylation, leading to activation of a transcriptional factor, STAT5 (signal…”
BackgroundBuettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,202
Oxygen sensing and molecular adaptation to hypoxia
Bunn, H. F., & Poyton, R. O. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.3.839 · Cited by 1,172 · cited 2×
“Since Epo is a secreted protein (3,4) with hypoxia stimulating its secretion (22,23), and since tumours are hypoxic (29), we measured with an enzyme-linked assay (30) Epo protein in each culture medium under normoxia and anoxia.”
BackgroundMethodErythropoietin: structure, control of production, and function
Jelkmann, W. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.2.449 · Cited by 1,151
In vivo evidence that erythropoietin protects neurons from ischemic damage
Sakanaka, M., Wen, T.-C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., & Sasaki, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4635 · Cited by 949 · cited 1×
“Epo prevents ischaemia-induced and toxic-stressed death of neurons in vivo ( 19 ,20), and apoptotic neuronal death in the developing brain (21).”
BackgroundTumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858 · cited 2×
“Angiogenesis is essential for the development of malignant tumours: some angiogenesis inhibitors and inhibition of the Raf-1 gene expressed on capillary endothelium (38) suppress the proliferation of endothelial cells and lead to the regression of established tumours.”
BackgroundErythropoietin Retards DNA Breakdown and Prevents Programmed Death in Erythroid Progenitor Cells
Koury, M. J., & Bondurant, M. C. (1990) · Science · doi:10.1126/science.2326648 · Cited by 812 · cited 1×
“In erythropoiesis, Epo prevents apoptotic death of Epo-responsive erythroid precursor cells (1) and stimulates their proliferation and differentiation into erythrocytes (2-4).”
BackgroundMorishita, E., Masuda, S., Nagao, M., Yasuda, Y., & Sasaki, R. (1996) · Neuroscience · doi:10.1016/s0306-4522(96)00306-5 · Cited by 661 · cited 1×
“In fact, Epo shows new physiological functions in the brain; neurons express EpoR (10, 13 ) and astrocytes produce Epo (10,12).”
BackgroundSelf-citationErythropoietin receptor mRNA expression in human endothelial cells.
Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E. S., Kessimian, N., & Noguchi, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3974 · Cited by 570 · cited 2×
“On the contrary, Epo-EpoR signalling acts as a mitogen in the endothelium where EpoR mRNA is present (17,18) through tyrosine phosphorylation of proteins including phosphorylation of STAT5 (39).”
BackgroundErythropoietin Gene Expression in Human, Monkey and Murine Brain
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Oigicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., & Gassmann, M. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01252.x · Cited by 552 · cited 2×
“In fact, Epo shows new physiological functions in the brain; neurons express EpoR (10, 13) and astrocytes produce Epo (10, 12).”
BackgroundLocalization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization
Koury, S., Bondurant, M., & Koury, M. (1988) · Blood · doi:10.1182/blood.v71.2.524.524 · Cited by 477
A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes.
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M., & Sasaki, R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32195-6 · Cited by 464
Masuda, S., Nagao, M., Takahata, K., Konishi, Y., Gallyas, F., Tabira, T., & Sasaki, R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82112-3 · Cited by 421 · cited 2×
“In fact, Epo shows new physiological functions in the brain; neurons express EpoR (10, 13) and astrocytes produce Epo (10, 12).”
BackgroundErythropoietin receptor signalling is required for normal brain development
Yu, X., Shacka, J. J., Eells, J. B., Suarez-Quian, C., Przygodzki, R. M., Beleslin-Cokic, B., Lin, C.-S., Nikodem, V. M., Hempstead, B., Flanders, K. C., et al. (2002) · Development · doi:10.1242/dev.129.2.505 · Cited by 367
The regulated expression of erythropoietin by two human hepatoma cell lines.
Goldberg, M. A., Glass, G. A., Cunningham, J. M., & Bunn, H. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7972 · Cited by 357 · cited 1×
“Then, we confirmed with the use of RT-PCR analysis the expression of Epo and EpoR mRNA in all cell lines including HepG2, which expresses Epo mRNA (27), and UT-7, which expresses EpoR mRNA (28).”
MethodStructure, function, and activation of the erythropoietin receptor
Youssoufian, H., Longmore, G., Neumann, D., Yoshimura, A., & Lodish, H. (1993) · Blood · doi:10.1182/blood.v81.9.2223.2223 · Cited by 355 · cited 3×
“In erythropoiesis, Epo prevents apoptotic death of Epo-responsive erythroid precursor cells (1) and stimulates their proliferation and differentiation into erythrocytes (2-4).”
BackgroundMethodEstrogen and Angiogenesis: A Review
Losordo, D. W., & Isner, J. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.6 · Cited by 352
Hematopoietic development of embryonic stem cells in vitro: cytokine and receptor gene expression.
Schmitt, R. M., Bruyns, E., & Snodgrass, H. R. (1991) · Genes & Development · doi:10.1101/gad.5.5.728 · Cited by 321 · cited 3×
“In addition to these organs, there is increasing evidence that many non-haematopoietic organs and tissues express Epo and EpoR; embryonic stem cells ( 8 ), the embryo proper including its developing nervous system (9), brain (10‐13), uterus (14) and ovary (15,16) express Epo; and endothelial cells (17,18), embryonic s…”
BackgroundInfluentialSadamoto, Y., Igase, K., Sakanaka, M., Sato, K., Otsuka, H., Sakaki, S., Masuda, S., & Sasaki, R. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9748 · Cited by 304 · cited 1×
“Epo prevents ischemia-induced and toxic-stressed death of neurons in vivo (19,20), and apoptotic neuronal death in the developing brain (21).”
BackgroundYasuda, Y., Masuda, S., Chikuma, M., Inoue, K., Nagao, M., & Sasaki, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25381 · Cited by 262 · cited 5×
“In the uterus, Epo plays an important role in angiogenesis via EpoR expressed in vascular endothelial cells of the uterine endometrium (14).”
BackgroundSelf-citationErythropoietin receptor characteristics on primary human erythroid cells
Broudy, V., Lin, N., Brice, M., Nakamoto, B., & Papayannopoulou, T. (1991) · Blood · doi:10.1182/blood.v77.12.2583.2583 · Cited by 255
Brain Capillary Endothelial Cells Express two forms of Erythropoietin Receptor mRNA
Yamaji, R., Okada, T., Moriya, M., Naito, M., Tsuruo, T., Miyatake, K., & Nakano, Y. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0494u.x · Cited by 238 · cited 2×
“On the contrary, Epo-EpoR signalling acts as a mitogen in the endothelium where EpoR mRNA is present (17,18) through tyrosine phosphorylation of proteins including phosphorylation of STAT5 (39).”
BackgroundErythropoietin stimulates proliferation of human renal carcinoma cells
Westenfelder, C., & Baranowski, R. L. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00211.x · Cited by 222 · cited 2×
“However, nobody had noted that Epo is involved in the development of kidney cancer until Westenfelder and Baranowski (36) noted this possibility, although it was known to be a cause of polycythaemia associated with autocrine Epo in tumours.”
BackgroundTumor Oxygenation: A New Predictive Parameter in Locally Advanced Cancer of the Uterine Cervix
Höckel, M., Vorndran, B., Schlenger, K., Baußmann, E., & Knapstein, P. G. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1262 · Cited by 184 · cited 1×
“As Epo is a secreted protein (3,4) with hypoxia stimulating its secretion (22,23), and as tumours are hypoxic ( 29 ), we measured with an enzyme-linked assay (30) Epo protein in each culture medium under normoxia and anoxia.”
MethodCarroll, M. P., Spivak, J. L., McMahon, M., Weich, N., Rapp, U. R., & May, W. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98572-8 · Cited by 176 · cited 1×
“Former reports described a relationship between Raf-1 and Epo signalling; Epo activates Raf-1 and activated Raf-1 is necessary for Epo and IL3 growth signalling pathways (40); in a UT-7 cell line Epo and Raf-1 activate MAP-kinase (41).”
BackgroundWickrema, A., Krantz, S., Winkelmann, J., & Bondurant, M. (1992) · Blood · doi:10.1182/blood.v80.8.1940.1940 · Cited by 147
Hou, Q., & Gorski, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9460 · Cited by 143 · cited 1×
“Since ES cells express mRNAs for Epo and EpoR (8), since blastocysts express estrogen receptor mRNA (45), and since E2 has an angiogenic capability (46), Epo induced by E2 may operate in these embryoid bodies, and simultaneous induction of VEGF and E2 from host blood may co-operate in leading to their growth.”
BackgroundDa Silva, J., Lacombe, C., Bruneval, P., Casadevall, N., Leporrier, M., Camilleri, J., Bariety, J., Tambourin, P., & Varet, B. (1990) · Blood · doi:10.1182/blood.v75.3.577.577 · Cited by 132
Yasuda, Y. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1797 · Cited by 115 · cited 10×
“We have detected previously the signal transduction of Epo by deprivation of Epo signal in blocks of uterine and ovarian ADC in vitro by injections of antibody to Epo or of soluble EpoR receptor ( 16 ).”
BackgroundMethodSelf-citationWickrema, A., Krantz, S. B., Winkelmann, J., et al. (1992) · Blood · doi:10.1182/blood.v80.8.1940.bloodjournal8081940 · Cited by 108 · cited 1×
“Moreover, during erythropoiesis, rigid regulation and control of EpoR is evident: the number of EpoR sites is 1,000 per cell in CFU-E and 200 per cell in erythroblasts, but there is no site in reticulocytes in human bone marrow (6); EpoR mRNA is stable with a mRNA half-life of only 90 min in human erythroid progenitor…”
BackgroundYasuda, Y., Musha, T., Tanaka, H., Fujita, Y., Fujita, H., Utsumi, H., Matsuo, T., Masuda, S., Nagao, M., Sasaki, R., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1666 · Cited by 101 · cited 3×
“their destruction, as seen in the xenografts of ovarian and uterine cancers (24)? We injected subcutaneously HMV1, G361, P39, 220, SCH, DLD1, A549, SBC3, Hela, PC-3 and HepG2 cell lines into nude mice and confirmed their transplantability: tumour swelling within 1 week for HepG2, up to 8 weeks for G361.”
BackgroundSelf-citationJohnson, D. L., Farrell, F. X., Barbone, F. P., McMahon, F. J., Tullai, J., Hoey, K., Livnah, O., Wrighton, N. C., Middleton, S. A., Loughney, D. A., et al. (1998) · Biochemistry · doi:10.1021/bi971956y · Cited by 100
Peripheral amino acid levels in patients with cancer
Clarke, E. F., Lewis, A. M., & Waterhouse, C. (1978) · Cancer · doi:10.1002/1097-0142(197812)42:6<2675::aid-cncr2820420624>3.0.co;2-g · Cited by 85
Signal transduction of erythropoietin in endothelial cells
Haller, H. G., Christel, C., Dannenberg, L., Thiele, P., Lindschau, C., & Luft, F. C. (1996) · Kidney International · doi:10.1038/ki.1996.339 · Cited by 80 · cited 11×
“Furthermore, we have reported that the proliferation and survival of uterine and ovarian cancers depend on the Abbreviations: ADC, adenocarcinoma; E2, estradiol-17b; EMP1, erythropoietin mimetic peptide 1; EMP9, erythropoietin mimetic peptide 9; Epo, erythropoietin; EpoR, erythropoietin receptor; HIF, hypoxia-inducibl…”
BackgroundInfluentialGoto, M., Murakami, A., Akai, K., Kawanishi, G., Ueda, M., Chiba, H., & Sasaki, R. (1989) · Blood · doi:10.1182/blood.v74.4.1415.1415 · Cited by 78
Gobert, S., Duprez, V., Lacombe, C., Gisselbrecht, S., & Mayeux, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.075_c.x · Cited by 69 · cited 1×
“Former reports described a relationship between Raf-1 and Epo signalling; Epo activates Raf-1 and activated Raf-1 is necessary for Epo and interleukin 3 growth signalling pathways (40); in a UT-7 cell line Epo and Raf-1 activate mitogen-activated protein (MAP)-kinase ( 41 ).”
BackgroundExpression of erythropoietin in human female reproductive organs.
Yasuda, Y., Fujita, Y., Musha, T., Tanaka, H., Shiokawa, S., Nakamatsu, K., Mori, S., Matsuo, T., & Nakamura, Y. (2001) · PubMed · Cited by 64
Self-citationTrimble, M. S., Caro, J., Talalla, A., & Brain, M. C. (1991) · Blood · doi:10.1182/blood.v78.3.599.599 · Cited by 60
Localization of Erythropoietin and Erythropoietin‐Receptor in Postimplantation Mouse Embryos
Yasuda, Y., Nagao, M., Okano, M., Masuda, S., Sasaki, R., Konishi, H., & Tanimura, T. (1993) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.1993.00711.x · Cited by 59 · cited 2×
“cell lines (9), cryosections of xenografts (24) and for staining specificity of each”
BackgroundSelf-citationKomatsu, N., & Fujita, H. (1993) · PubMed · Cited by 18
Katsuoka, Y., McGonigle, R. J., Rege, A. B., Beckman, B. S., & Fisher, J. W. (1983) · PubMed · Cited by 17
Utsumi, H., & Elkind, M. M. (1993) · Radiation Oncology Investigations · doi:10.1002/roi.2970010106 · Cited by 6 · cited 1×
“Results Expression of Epo and EpoR in malignant human cell lines We examined cell lines established from patients’ tumours and from commercial sources including cells with and without p53 or mitochondria and those resistant or sensitive to radiation (26) or chemotherapy.”
Background
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Emerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
“Third, many malignant tumours express both erythropoietin and EPOR, and tumour growth is supported by erythropoietin both in vitro and in vivo”
BackgroundErythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
Metadata
- Authors
- Yasuda, Y.
- Affiliations
- Kindai University (JP)
- Corresponding author
- Yasuda, Y.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-24
- Volume
- 24
- Issue
- 6
- Pages
- 1021-1029
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2102546064
- Cited by
- 257
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 9 · 2016: 10 · 2015: 6 · 2014: 7 · 2013: 10 · 2012: 12
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- erythropoietin, erythropoietin receptor, tumor growth, STAT5 phosphorylation, hypoxia, angiogenesis, tumor cell survival, choriocarcinoma, melanoma, malignant cell lines, xenografts, anti-angiogenic therapy
- MeSH terms
- Cell Division, Erythropoietin, Humans, Neoplasms, Neovascularization, Pathologic, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Receptors, Erythropoietin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.